Defendant
7 cases as defendant.
Company overview. Cipla Limited ("Cipla") is an Indian pharmaceutical company founded in 1935 by Dr. K.A. Hamied and headquartered at Cipla House, Lower Parel, Mumbai. It is publicly listed on the BSE (500087), NSE (CIPLA) and the Luxembourg exchange (GDRs); it is not a subsidiary. Cipla reports roughly 30,000+ employees globally and revenue from operations of about ₹27,000 crore (roughly US$3.2 billion) in FY2024-25. It is majority-independent, with the Hamied family historically associated with its leadership (Dr. Y.K. Hamied, Non-Executive Chairman).
Products / services / operations. Cipla is an operating generics and branded-generics manufacturer, not an NPE. Its portfolio spans complex generics and drugs in respiratory, anti-retroviral/HIV, urology, cardiology, anti-infective, CNS and oncology, plus active pharmaceutical ingredients (APIs), biosimilars and consumer healthcare (Cipla Health). It operates around 46 manufacturing sites producing 50+ dosage forms and 1,500+ products across roughly 70-80 markets, with India, South Africa and North America as core markets; its U.S. business (Cipla USA) reported about US$934 million in FY2024-25 revenue, with a respiratory and peptide/505(b)(2) pipeline.
Patent-litigation posture. Cipla appears once in the tracked data, solely as a defendant (0 plaintiff cases, 1 defendant case). This is the profile of an operating company being sued, not a patent asserter. The single tracked suit was filed in the U.S. District Court for the District of Delaware — a common venue for Hatch-Waxman ANDA disputes — rather than a plaintiff-friendly NPE venue such as the Eastern District of Texas.
Notable case. Helsinn Healthcare S.A. et al. v. Cipla Ltd. (D. Del., filed 2013-04-16) was a Hatch-Waxman infringement action arising from Cipla's Paragraph IV ANDA seeking to market generic palonosetron hydrochloride, a generic version of Helsinn's Aloxi (used to prevent chemotherapy-induced nausea and vomiting). Cipla and Cipla USA were co-defendants alongside other generics in related filings; the underlying Helsinn palonosetron patent family was also the subject of the Supreme Court's 2019 Helsinn v. Teva on-sale-bar decision. No merits determination in Cipla's case is asserted here.
Hatch-Waxman ANDA litigation concerning Cipla ANDA No. 219718 (1/2/3/4 mg). Consent judgment entered Sept. 11, 2025; case closed Sept. 17, 2025. Patents-in-suit: 8,828,427; 9,993,467; 10,555,939. Injunction until expiration; no damages.
Celgene's consolidated action against Cipla consolidated 2:17-cv-06163 and 2:18-cv-08964. It settled in Dec. 2020; the consolidated Cipla action carried the '357, '219, and '598 patents from 2:18-cv-08964.
Celgene sued Cipla and a Cipla USA affiliate in D.N.J. over generic lenalidomide. The asserted patents included '800, '217, '569, '498, '095, '621, '622, '740, '717, and '120; a stipulated consent judgment was entered December 14, 2020. The case number was not confirmed in the sources.
Celgene sued Cipla in a D.N.J. ANDA action involving ANDA No. 210435; the case was consolidated into 2:19-cv-14731 on June 8, 2020, and settled on December 11, 2020.
Celgene sued Cipla Ltd. in D.N.J. in 2017, asserting U.S. 7,855,217. Celgene stipulated to dismissal of the '217 count and gave a covenant not to sue on August 16, 2018; the case later settled on December 10, 2020. The docket number was not confirmed.
D. Del. action asserting the '725 patent against Cipla. Settled/terminated.
Delaware Hatch-Waxman ANDA action asserting the '424 patent against Cipla Ltd.; terminated in 2015.